In conclusion, our study showed that ANXA1 is a candidate for target therapy toward NSCLC and targeting ANXA1 may enhance the effects of EGFR-TKI in lung cancer cells with EGFR mutations. The gene discussed is ANXA1; the disease is lung carcinoma.